AISLING CAPITAL MANAGEMENT LP Holdings

AISLING CAPITAL MANAGEMENT LP is an investment fund managing more than 150.59M US dollars. The largest holdings include BridgeBio Pharma, Syndax Pharmaceuticals and Verona Pharma. In Q1 2021 the fund bought assets of total value of 121.12M US dollars and sold assets of total value of 462K US dollars.

$150.59M

portfolio value

+8.43%

quarter

-63.48%

1 year

-105.38%

3 years

AISLING CAPITAL MANAGEMENT LP portfolio changes

Portfolio changes (number of shares)
Period	Buy	Sel
Q1 2019	8956000	1615000
Q3 2019	-1168000	12021000
Q2 2020	15218000	4627000
Q4 2020	29306000	556000
Q1 2021	121121000	462000

AISLING CAPITAL MANAGEMENT LP 13F holdings

Stock	Position type	Portfolio share	Portfolio value	Avg. open price	Current price	P/L	Last change
Biotechnology BridgeBio Pharma, Inc. Portfolio share: 40.05% Portfolio value: 60.31M Avg. open price: $68.63 Current price: $9.47 P/L: -86.20% Bought +52.11% shares Q1 2021	share	40.05%	60.31M	$68.63	$9.47	-86.20%	Bought +52.11% shares Q1 2021
Biotechnology Syndax Pharmaceuticals, Inc. Portfolio share: 16.36% Portfolio value: 24.63M Avg. open price: $10.97 Current price: $25.07 P/L: +128.53% Bought +17.14% shares Q2 2020	share	16.36%	24.63M	$10.97	$25.07	+128.53%	Bought +17.14% shares Q2 2020
Biotechnology Verona Pharma plc Portfolio share: 9.04% Portfolio value: 13.61M Avg. open price: $4.68 Current price: $13.94 P/L: +197.86% Bought +200.38% shares Q3 2020	share	9.04%	13.61M	$4.68	$13.94	+197.86%	Bought +200.38% shares Q3 2020
Biotechnology Monte Rosa Therapeutics, Inc. Portfolio share: 7.99% Portfolio value: 12.02M Avg. open price: N/A Current price: $9.72 P/L: N/A N/A Q2 2021	share	7.99%	12.02M	N/A	$9.72	N/A	N/A Q2 2021
Diagnostics & Research Aclaris Therapeutics, Inc. Portfolio share: 6.63% Portfolio value: 9.98M Avg. open price: N/A Current price: $16.64 P/L: N/A N/A Q4 2018	share	6.63%	9.98M	N/A	$16.64	N/A	N/A Q4 2018
Biotechnology Biomea Fusion, Inc. Portfolio share: 5.19% Portfolio value: 7.81M Avg. open price: N/A Current price: $6.96 P/L: N/A N/A Q2 2021	share	5.19%	7.81M	N/A	$6.96	N/A	N/A Q2 2021
Biotechnology Nuvation Bio Inc. Portfolio share: 3.78% Portfolio value: 5.69M Avg. open price: N/A Current price: $2 P/L: N/A N/A Q1 2021	share	3.78%	5.69M	N/A	$2	N/A	N/A Q1 2021
Biotechnology Poseida Therapeutics, Inc. Portfolio share: 2.45% Portfolio value: 3.68M Avg. open price: N/A Current price: $4.92 P/L: N/A N/A Q3 2020	share	2.45%	3.68M	N/A	$4.92	N/A	N/A Q3 2020
Biotechnology Elevation Oncology, Inc. Portfolio share: 2.13% Portfolio value: 3.20M Avg. open price: N/A Current price: $0.91 P/L: N/A N/A Q2 2021	share	2.13%	3.20M	N/A	$0.91	N/A	N/A Q2 2021
Biotechnology Reneo Pharmaceuticals, Inc. Portfolio share: 1.97% Portfolio value: 2.96M Avg. open price: N/A Current price: $2.19 P/L: N/A N/A Q2 2021	share	1.97%	2.96M	N/A	$2.19	N/A	N/A Q2 2021
Biotechnology Spruce Biosciences, Inc. Portfolio share: 1.10% Portfolio value: 1.65M Avg. open price: N/A Current price: $1.15 P/L: N/A N/A Q4 2020	share	1.10%	1.65M	N/A	$1.15	N/A	N/A Q4 2020
Biotechnology Viracta Therapeutics, Inc. Portfolio share: 0.82% Portfolio value: 1.23M Avg. open price: N/A Current price: $2.12 P/L: N/A N/A Q2 2021	share	0.82%	1.23M	N/A	$2.12	N/A	N/A Q2 2021
Biotechnology Marker Therapeutics, Inc. Portfolio share: 0.77% Portfolio value: 1.16M Avg. open price: $1.45 Current price: $0.3 P/L: -79.39% Bought +57.14% shares Q1 2021	share	0.77%	1.16M	$1.45	$0.3	-79.39%	Bought +57.14% shares Q1 2021
Biotechnology Aeglea BioTherapeutics, Inc. Portfolio share: 0.59% Portfolio value: 890K Avg. open price: $6.16 Current price: $0.5 P/L: -91.88% Bought +30.98% shares Q2 2020	share	0.59%	890K	$6.16	$0.5	-91.88%	Bought +30.98% shares Q2 2020
Biotechnology AVROBIO, Inc. Portfolio share: 0.43% Portfolio value: 646K Avg. open price: $18.02 Current price: $0.87 P/L: -95.16% Bought +13.07% shares Q1 2020	share	0.43%	646K	$18.02	$0.87	-95.16%	Bought +13.07% shares Q1 2020
Biotechnology Atreca, Inc. Portfolio share: 0.40% Portfolio value: 609K Avg. open price: N/A Current price: $1.04 P/L: N/A N/A Q2 2019	share	0.40%	609K	N/A	$1.04	N/A	N/A Q2 2019
Biotechnology Talaris Therapeutics, Inc. Portfolio share: 0.31% Portfolio value: 460K Avg. open price: N/A Current price: $1.45 P/L: N/A Sold -74.37% shares Q3 2022	share	0.31%	460K	N/A	$1.45	N/A	Sold -74.37% shares Q3 2022
Biotechnology Zosano Pharma Corporation Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $2.79 Current price: $0.56 P/L: -80.02% Sold -100.00% shares Q3 2022	share	0.00%	0	$2.79	$0.56	-80.02%	Sold -100.00% shares Q3 2022
Biotechnology Nabriva Therapeutics plc Portfolio share: 0.00% Portfolio value: 0 Avg. open price: $24.3 Current price: $2.13 P/L: -91.23% Sold -100.00% shares Q3 2022	share	0.00%	0	$24.3	$2.13	-91.23%	Sold -100.00% shares Q3 2022

Showing TOP 19 AISLING CAPITAL MANAGEMENT LP's 13F holdings.

Frequently Asked Questions (FAQ)

What is the biggest position of AISLING CAPITAL MANAGEMENT LP?

The biggest position of the AISLING CAPITAL MANAGEMENT LP is BridgeBio Pharma, Inc. (BBIO) with 40.05% portfolio share worth of 60.32M US dollars.

Top 5 AISLING CAPITAL MANAGEMENT LP's holdings represent 80.07% of the portfolio:

BridgeBio Pharma, Inc. (BBIO) – 40.05%
Syndax Pharmaceuticals, Inc. (SNDX) – 16.36%
Verona Pharma plc (VRNA) – 9.04%
Monte Rosa Therapeutics, Inc. (GLUE) – 7.99%
Aclaris Therapeutics, Inc. (ACRS) – 6.63%

Who is the portfolio manager of AISLING CAPITAL MANAGEMENT LP?

The portfolio manager of the AISLING CAPITAL MANAGEMENT LP is .

What is the total asset value of the AISLING CAPITAL MANAGEMENT LP portfolio?

AISLING CAPITAL MANAGEMENT LP total asset value (portfolio value) is 150.59M US dollars.

Who is ?

is the portfolio manager of the AISLING CAPITAL MANAGEMENT LP.

What is (AISLING CAPITAL MANAGEMENT LP) fund performance?

AISLING CAPITAL MANAGEMENT LP's quarterly performance is +8.43%, annualy -63.48%. In the past 3 years, the value of 's portfolio has decreased by -105%.

What is the AISLING CAPITAL MANAGEMENT LP CIK?

AISLING CAPITAL MANAGEMENT LP's Central Index Key is 0001766721 .